Ethanol Extract of Vicatia thibetica de Boiss. Improves Chronic Atrophic Gastritis in Rats via the HO-1/Nrf2 and Myd88/AKT/PI3K Signaling Pathways

WANGJIECIREN, LAN Jun, DAWAZHUOMA, CHEN Min, DU Jinyang, YE Bengui

Abstract

Objective 

The ameliorative effects of the ethanol extract of Vicatia thibetica de Boiss. (VTDB) on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced chronic atrophic gastritis (CAG) in rats were investigated, and its mechanism of action was preliminarily explored.

Methods 

Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was used to analyze the chemical constituents of VTDB. A rat CAG model was established using MNNG induction combined with irregular feeding. Seventy-two healthy male SD rats were randomly divided into six groups: normal control, model, low-dose VTDB (157 mg/[kg·d]), medium-dose VTDB (314 mg/[kg·d]), high-dose VTDB (628 mg/[kg·d]), and positive control (Vatacoenayme) (216 mg/[kg·d]), with 12 rats in each group. HE staining was used to observe pathological changes in the gastric mucosa of each group. ELISA was performed to measure serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and inflammatory factors (TNF-α, IL-6, and IL-10). Levels of malondialdehyde (MDA) and superoxide dismutase (SOD) activity in gastric tissues were determined. Western blot was used to measure the expression levels of heme oxygenase-1 (HO-1)/nuclear factor erythroid-2-related factor 2 (Nrf2) and myeloid differentiation primary response protein 88 (MyD88)/protein kinase B (AKT)/phosphatidylinositide 3-kinase (PI3K) signaling pathway proteins in gastric tissues.

Results 

By comparing retention times, mass spectral fragmentation patterns, and matching with the ESI (±)-MS/MS database, a total of 89 chemical constituents–primarily fatty acids, phenolic acids, and coumarins–were identified in VTDB. HE staining indicated that VTDB partially improved gastric mucosal damage in CAG rats. ELISA showed that, compared with the model group, the VTDB-treated groups had increased serum levels of PGⅠ, PGⅡ, and PGR (PGⅠ/PGⅡ) (P < 0.05) and decreased levels of gastrin 17 (G-17) (P < 0.05). In the low-, medium-, and high-dose groups, serum TNF-α levels decreased, and in the low- and high-dose groups, serum IL-6 secretion decreased (P < 0.05), while serum IL-10 secretion increased in the high-dose group (P < 0.001). In the VTDB medium- and high-dose groups, MDA levels in gastric tissue decreased (P < 0.01), and SOD activity increased in the VTDB low-, medium-, and high-dose groups (P < 0.05). Western blot results showed that HO-1 levels increased in the high-dose VTDB group and Nrf2 levels increased in the low-, medium-, and high-dose VTDB groups (P < 0.001). MyD88 levels decreased in the VTDB low- and high-dose groups, while AKT and PI3K levels decreased in the VTDB medium- and high-dose groups (P < 0.05), indicating that VTDB can modulate the expression of HO-1/Nrf2 and MyD88/AKT/PI3K signaling pathway proteins.

Conclusion 

VTDB reduces gastric damage and inflammation in CAG rats by inhibiting lipid peroxidation and inflammatory processes through its effects on the HO-1/Nrf2 and MyD88/AKT/PI3K signaling pathways.

 

Keywords: Ethanol extract of Vicatia thibetica de Boiss, Chemical composition analysis, Chronic atrophic gastritis, Protective effect

 

Full Text:

PDF


References


LI J, PAN J, XIAO D, et al. Chronic atrophic gastritis and risk of incident upper gastrointestinal cancers: a systematic review and meta-analysis. J Transl Med, 2024, 22(1): 429. doi: 10.1186/s12967-023-04736-w.

SHAH S C, WANG A Y, WALLACE M B, et al. AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review. Gastroenterology, 2025, 168(2): 405-416. e1. doi: 10.1053/j.gastro.2024.11.001.

LIU Y, XU W Q, GUO M. Research progress on the mechanism of energy metabolic reprogramming in the "inflammation to cancer" transformation of chronic atrophic gastritis. Journal of Modern Oncology, 2024, 32(8): 1567-1572. doi: 10.3969/j.issn.1672-4992.2024.08.036.

ZHOU P, YANG T, XU M, et al. 16S rRNA sequencing-based evaluation of the protective effects of Hua-Zhuo-Jie-Du on rats with chronic atrophic gastritis. BMC Complement Med Ther, 2022, 22(1): 71. doi: 10.1186/s12906-022-03542-z.

CHAPELLE N, PETRYSZYN P, BLIN J, et al. A panel of stomach-specific biomarkers (GastroPanel ) for the diagnosis of atrophic gastritis: a prospective, multicenter study in a low gastric cancer incidence area. Helicobacter, 2020, 25(5): e12727. doi: 10.1111/hel.12727.

DELGADO-GUILLENA P, VELAMAZAN-SANDALINAS R, JIMÉNEZ SÁNCHEZ J, et al. History and clinical guidelines for chronic atrophic gastritis and the assessment of gastric cancer risk. Gastroenterol Hepatol, 2023, 46(9): 727-731. doi: 10.1016/j.gastrohep.2023.09.001.

WENG J, WU X F, SHAO P, et al. Medicine for chronic atrophic gastritis: a systematic review, meta-and network pharmacology analysis. Ann Med, 2023, 55(2): 2299352. doi: 10.1080/07853890.2023.2299352.

YANAKA A. Role of sulforaphane in protection of gastrointestinal tract against H. pylori and NSAID-induced oxidative stress. Curr Pharm Des, 2017, 23(27): 4066-4075. doi: 10.2174/1381612823666170207103943.

WANG R, ZHAO Y, ZHOU L, et al. Costunolide ameliorates MNNG-induced chronic atrophic gastritis through inhibiting oxidative stress and DNA damage via activation of Nrf2. Phytomedicine, 2024, 130: 155581. doi: 10.1016/j.phymed.2024.155581.

LIU S, ZHANG T, FANG L, et al. Integrative pharmacological analysis of modified Zuojin formula: Inhibiting the HIF-1α-mediated glycolytic pathway in chronic atrophic gastritis. J Ethnopharmacol, 2025, 339: 119136. doi: 10.1016/j.jep.2024.119136.

CAIRANGNANJIA, DUOJIERENQING, WENCHENGDANGZHI, et al. Application of Tibetan celery in Tibetan medicine. China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(1): 535-537.

LI Y, LI H, LUO T, et al. Intensity-dependent mass search for improving metabolite database matches in chemical isotope labeling LC-QTOF-MS-based metabolomics. Anal Chim Acta, 2023, 1272: 341467. doi: 10.1016/j. aca.2023.341467.

SANTOS JUNIOR C M, SILVA S M C, SALES E M, et al. Coumarins from Rutaceae: chemical diversity and biological activities. Fitoterapia, 2023, 168: 105489. doi: 10.1016/j.fitote.2023.105489.

ROHMAN N, ARDIANSAH B, WUKIRSARI T, et al. Recent trends in the synthesis and bioactivity of coumarin, coumarin-chalcone, and coumarin-triazole molecular hybrids. Molecules, 2024, 29(5): 1026. doi: 10.3390/molecules29051026.

SUN W, SHAHRAJABIAN M H. Therapeutic potential of phenolic compounds in medicinal plants-natural health products for human health. Molecules, 2023, 28(4): 1845. doi: 10.3390/molecules28041845.

Chinese Society of Gastroenterology, Cancer Collaboration Group of Chinese Society of Gastroenterology, Chinese Medical Association. Guidelines for Diagnosis and Treatment of Chronic Gastritis in China (2022, Shanghai). Chinese Journal of Gastroenterology, 2023, 28(3): 149-180. doi: 10.3969/j.issn.1008-7125.2023.03.004.

WANG Y G, HAO X Y, YU R J, et al. Effect of Huazhuojiedu Formula on Hippo/TAZ signal channel and related proteins TAZ, LATS2, MST1 in rats with chronic atrophic gastritis. Pharmacology and Clinics of Chinese Materia Medica, 2019, 35(3): 105-110. doi: 10.13412/j.cnki.zyyl.2019.03.023.

AN Y, CHEN W G, CHEN B S, et al. Effects of Huangqi Guizhi Decoction on the expression levels of serum gastrin and motilin in rats with chronic


Refbacks

  • There are currently no refbacks.